Orthocell has today announced that the Company has submitted a regulatory application to the Health Services Authority of Singapore for approval to market and sell Remplirâ„¢ for use in peripheral nerve repair procedures
The Hon Kim Beazley AC Joins Orthocell Board
Orthocell has appointed Australia’s former US ambassador and Governor of Western Australia, The Hon Kim Beazley AC, as an Independent Non-Executive Director to the Board.
ABC News | Tennis elbow treatment trial successes offer hope for sufferers wary of surgery
Orthocell recently released compelling new data from our clinical trial comparing the effectiveness of our tendon cell therapy (OrthoATI™) to surgery, in the treatment of severe, chronic lateral epicondylitis – also known as tennis elbow.
This week, Orthocell was featured in a national news story (television, radio, online) by ABC News reporter, Erin Somerville, who shared the story of Annette Skirka – a patient whose debilitating experience with tennis elbow prevented her from pursuing her passion for mountaineering. This led her to explore a number of treatment options, before eventually participating in our clinical trial.
Click here to read Annette’s story.
Click here to watch the ABC News segment
Positive clinical results for OrthoATIâ„¢
Orthocell has today released positive results from our clinical study comparing OrthoATIâ„¢ to surgery for the treatment of severe chronic lateral epicondylitis (LE) – also known as tennis elbow.
Professor Fiona Wood AM joins Orthocell Board
Orthocell has today announced the appointment of one of Australia’s most innovative and respected plastic and reconstructive surgeons and researchers, Professor Fiona Wood AM, as an independent Non-Executive Director.
Quarterly Report – Period To 30 September 2023
Orthocell has today published its Quarterly Report for the period ended 30 September 2023.
Striate+â„¢ re-certified under new European medical device regulations
Orthocell has announced that Striate+â„¢dental membrane has received regulatory approval under the new European Medical Device Regulations (MDR).
Inaugural Nerve Transfer and Reconstruction Symposium
Orthocell was delighted to co-sponsor the inaugural Nerve Transfer and Reconstruction Symposium at the University of Western Australia last week.
VIDEO | Proactive Investors – May 2023
Orthocell’s MD Paul Anderson and John Van Der Wielen spoke with Andrew Scott at Proactive Investors about John’s appointment as independent non-executive chairman. John brings 35 years of global experience in wealth management, private banking, investments and health insurance, including considerable experience in corporate strategy, international growth initiatives, M&A transactions and engaging strategic investors.
New Bio-manufacturing Facility Launch Event
This week marks the official launch of Orthocell’s new GMP certified bio-manufacturing facility at the Company headquarters in Perth.